137 related articles for article (PubMed ID: 37838333)
1. The Therapeutic Aryl Hydrocarbon Receptor-Modulating Agent Tapinarof Regulates SEMA3A Expression in Human Keratinocytes through NRF2.
Tsuji G; Yumine A; Yamamura K; Takemura M; Kido-Nakahara M; Ito T; Nakahara T
J Invest Dermatol; 2024 Mar; 144(3):710-713.e8. PubMed ID: 37838333
[No Abstract] [Full Text] [Related]
2. IL-24 Negatively Regulates Keratinocyte Differentiation Induced by Tapinarof, an Aryl Hydrocarbon Receptor Modulator: Implication in the Treatment of Atopic Dermatitis.
Vu YH; Hashimoto-Hachiya A; Takemura M; Yumine A; Mitamura Y; Nakahara T; Furue M; Tsuji G
Int J Mol Sci; 2020 Dec; 21(24):. PubMed ID: 33321923
[TBL] [Abstract][Full Text] [Related]
3. Natural Compounds Tapinarof and
Tsuji G; Hashimoto-Hachiya A; Matsuda-Taniguchi T; Takai-Yumine A; Takemura M; Yan X; Furue M; Nakahara T
Front Immunol; 2022; 13():745997. PubMed ID: 35663970
[TBL] [Abstract][Full Text] [Related]
4. Tapinarof in the treatment of psoriasis: A review of the unique mechanism of action of a novel therapeutic aryl hydrocarbon receptor-modulating agent.
Bissonnette R; Stein Gold L; Rubenstein DS; Tallman AM; Armstrong A
J Am Acad Dermatol; 2021 Apr; 84(4):1059-1067. PubMed ID: 33157177
[TBL] [Abstract][Full Text] [Related]
5. Regulation of Filaggrin, Loricrin, and Involucrin by IL-4, IL-13, IL-17A, IL-22, AHR, and NRF2: Pathogenic Implications in Atopic Dermatitis.
Furue M
Int J Mol Sci; 2020 Jul; 21(15):. PubMed ID: 32751111
[TBL] [Abstract][Full Text] [Related]
6. Aryl hydrocarbon receptor/nuclear factor E2-related factor 2 (AHR/NRF2) signalling: A novel therapeutic target for atopic dermatitis.
Hwang J; Newton EM; Hsiao J; Shi VY
Exp Dermatol; 2022 Apr; 31(4):485-497. PubMed ID: 35174548
[TBL] [Abstract][Full Text] [Related]
7. The preponderance of evidence supports an aryl hydrocarbon receptor-dependent mechanism of action of tapinarof.
Bissonnette R; Gold LS; Rubenstein DS; Tallman AM; Armstrong AW
J Am Acad Dermatol; 2021 Jul; 85(1):e35-e36. PubMed ID: 33677005
[No Abstract] [Full Text] [Related]
8. Inhibition of aryl hydrocarbon receptor signaling and induction of NRF2-mediated antioxidant activity by cinnamaldehyde in human keratinocytes.
Uchi H; Yasumatsu M; Morino-Koga S; Mitoma C; Furue M
J Dermatol Sci; 2017 Jan; 85(1):36-43. PubMed ID: 27720465
[TBL] [Abstract][Full Text] [Related]
9. Identification of ketoconazole as an AhR-Nrf2 activator in cultured human keratinocytes: the basis of its anti-inflammatory effect.
Tsuji G; Takahara M; Uchi H; Matsuda T; Chiba T; Takeuchi S; Yasukawa F; Moroi Y; Furue M
J Invest Dermatol; 2012 Jan; 132(1):59-68. PubMed ID: 21753779
[TBL] [Abstract][Full Text] [Related]
10. Tapinarof Is a Natural AhR Agonist that Resolves Skin Inflammation in Mice and Humans.
Smith SH; Jayawickreme C; Rickard DJ; Nicodeme E; Bui T; Simmons C; Coquery CM; Neil J; Pryor WM; Mayhew D; Rajpal DK; Creech K; Furst S; Lee J; Wu D; Rastinejad F; Willson TM; Viviani F; Morris DC; Moore JT; Cote-Sierra J
J Invest Dermatol; 2017 Oct; 137(10):2110-2119. PubMed ID: 28595996
[TBL] [Abstract][Full Text] [Related]
11. Targeting the Aryl Hydrocarbon Receptor to Address the Challenges of Atopic Dermatitis.
Eichenfield LF; Silverberg JI; Hebert AA; Chovatiya R; Brown PM; McHale KA; Rubenstein DS; Tallman AM
J Drugs Dermatol; 2024 Feb; 23(2):23-28. PubMed ID: 38306128
[TBL] [Abstract][Full Text] [Related]
12. Z-Ligustilide inhibits benzo(a)pyrene-induced CYP1A1 upregulation in cultured human keratinocytes via ROS-dependent Nrf2 activation.
Wu Z; Uchi H; Morino-Koga S; Nakamura-Satomura A; Kita K; Shi W; Furue M
Exp Dermatol; 2014 Apr; 23(4):260-5. PubMed ID: 24588654
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and patient-reported outcomes from a phase 2b, randomized clinical trial of tapinarof cream for the treatment of adolescents and adults with atopic dermatitis.
Paller AS; Stein Gold L; Soung J; Tallman AM; Rubenstein DS; Gooderham M
J Am Acad Dermatol; 2021 Mar; 84(3):632-638. PubMed ID: 32502588
[TBL] [Abstract][Full Text] [Related]
14. The AhR-Nrf2 pathway in keratinocytes: on the road to chemoprevention?
Haarmann-Stemmann T; Abel J; Fritsche E; Krutmann J
J Invest Dermatol; 2012 Jan; 132(1):7-9. PubMed ID: 22158605
[TBL] [Abstract][Full Text] [Related]
15. Phase 3 Trials of Tapinarof Cream for Plaque Psoriasis.
Lebwohl MG; Stein Gold L; Strober B; Papp KA; Armstrong AW; Bagel J; Kircik L; Ehst B; Hong HC; Soung J; Fromowitz J; Guenthner S; Piscitelli SC; Rubenstein DS; Brown PM; Tallman AM; Bissonnette R
N Engl J Med; 2021 Dec; 385(24):2219-2229. PubMed ID: 34879448
[TBL] [Abstract][Full Text] [Related]
16. Tapinarof Cream 1%: First Approval.
Keam SJ
Drugs; 2022 Jul; 82(11):1221-1228. PubMed ID: 35939180
[TBL] [Abstract][Full Text] [Related]
17. Tapinarof to treat psoriasis.
Rodríguez Baisi K; Tollefson M
Drugs Today (Barc); 2020 Aug; 56(8):515-530. PubMed ID: 33025947
[TBL] [Abstract][Full Text] [Related]
18. Antioxidant soybean tar Glyteer rescues T-helper-mediated downregulation of filaggrin expression via aryl hydrocarbon receptor.
Takei K; Mitoma C; Hashimoto-Hachiya A; Uchi H; Takahara M; Tsuji G; Kido-Nakahara M; Nakahara T; Furue M
J Dermatol; 2015 Feb; 42(2):171-80. PubMed ID: 25482884
[TBL] [Abstract][Full Text] [Related]
19. The mode of action of tapinarof may not only depend on the activation of cutaneous aryl hydrocarbon receptor signaling but also on its antimicrobial activity.
Haarmann-Stemmann T; Sutter TR; Krutmann J; Esser C
J Am Acad Dermatol; 2021 Jul; 85(1):e33-e34. PubMed ID: 33677003
[No Abstract] [Full Text] [Related]
20. Palladium and Platinum Nanoparticles Activate AHR and NRF2 in Human Keratinocytes-Implications in Vitiligo Therapy.
Tsuji G; Hashimoto-Hachiya A; Takemura M; Kanemaru T; Ichihashi M; Furue M
J Invest Dermatol; 2017 Jul; 137(7):1582-1586. PubMed ID: 28300598
[No Abstract] [Full Text] [Related]
[Next] [New Search]
